Skip to main content

Alnylam Receives Undisclosed Milestone from Roche Under RNAi Rx Collaboration


Alnylam Pharmaceuticals said this week that it has received a milestone payment from Roche related to the initiation of pre-investigational new drug application studies for an RNAi therapeutic covered by a collaboration between the firms.

Financial details about the milestone were not disclosed.

The companies first began working together in 2007. Under that agreement, Roche acquired a non-exclusive license to use Alnylam's fundamental RNAi intellectual property to develop therapeutics in oncology, respiratory diseases, metabolic diseases, and certain liver diseases (see RNAi News, 7/12/2007).

In late 2009, Alnylam announced that the arrangement had advanced to the “RNAi therapeutic-collaboration phase,” under which the companies will jointly develop and commercialize specific, disease-target focused drug candidates based on the gene-silencing technology (see RNAi News, 11/5/2009).

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.